Disc Medicine Q2 net loss widens to $59.53 million; R&D expenses rise to $46.93 million
IRON•Cash position and outlook
Cash, cash equivalents and marketable securities fell to USD 717.75 million at June 30, 2026, from USD 791.15 million at end-2025; runway projected into 2029.
Bitopertin Phase 3 APOLLO topline data remains due in Q4 2026, with an FDA decision on a CRL response targeted for mid-2027.
Second-quarter results and expenses
Disc Medicine posted a wider Q2 net loss of USD 59.53 million, compared with a loss of USD 55.25 million a year earlier.
R&D spending rose to USD 46.93 million from USD 46.32 million, due to advancing selcodebart and DISC-3405 studies, manufacturing, and higher headcount.
SG&A expenses climbed to USD 18.14 million from USD 15.09 million on increased headcount.
